Supplemental data: 4TABLES

TABLE S1.Clinical and biological parameters of the control group.Abbreviations: TG, triglycerides; PL, phospholipids; NEFA, non-esterified fatty acid; TC, total cholesterol; cHDL, HDL cholesterol; cLDL, LDL cholesterol; apoA1, apolipoprotein A1; apoB. apolipoprotein B;HOMA-IR, homeostasis model assessment-insulin resistance; a.u., arbitrary units; CRP, C-reactive protein and PAI-1, plasminogen activator inhibitor-1.

Parameters / Control (n=23)
Satiety
Leptin (ng/mL plasma) / 15,0±0,9
Ghrelin (pg/mL plasma) / 132,0±0,3
Adiponectin (µg/mL plasma) / 18,1±2,3
Lipid metabolism
TG (mg/dL plasma) / 89 ± 9
PL (mM plasma) / 2,7±0,1
NEFA (mM plasma) / 9 ± 0
Chol (mg/dL plasma) / 164 ± 3
cLDL (mg/dL plasma) / 105 ± 4
cHDL (mg/dL plasma) / 74± 4
apo A1 (mg/dL plasma) / 197,5±6,4
apo B (mg/dL plasma) / 68,4±4,9
Insulin resistance
Insulin (UI/L plasma) / 11±1
Glucose (mg/dL plasma) / 72±2
HOMA-IR (a.u.) / 2.0±0.1
Inflammation
CRP (mg/L plasma) / 6,9±0,9
PAI-1 (ng/mL plasma) / 76,2±11,0

TABLE S2.Anthropometric and satiety parameters of morbidly obese patients with different BMIs.Data are expressed as the mean ± SEM. The DM-DL- group includes patients without Type 2diabetes mellitus (DM) and without dyslipidemia (DL)(healthy group). The DM-DL+ group includes patients who do not have DM but do have DL. The DM+DL+ group includes patients who have both DMand DL. The statistics were calculatedusing two-way ANOVA (anova-2) and Bonferroni post-tests and were used to study the interaction between the effects of comorbidities and the BMI effect. Abbreviations: SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.The level of significance was adjusted for multiple comparisons (Bonferroni correction/adjustment procedure) and were considered significant at p<0.01. One symbol, p<0.01; two symbols, 0.001; ns, non-significant.

Parameters / DM-DL- (n=10) / DM-DL+ (n=15) / DM+DL+ (n=7) / Anova-2, p value
Anthropometrics / BMI / OB / OB / OB / Comorbidities effect / BMI effect
Body weight (Kg) / <45 / 113.5±1.5 / 122.0±13.0 / 116.8±15.8
45-50 / 129.3±13.7 / 123.7±6.7 / 107.5±9.5
>50 / 145.5±7.7 / 144.5±5.0 / 130.2±6.2 / ns / ns
BMI (Kg/m2) / <45 / 38.8±1.9 / 43.1±1.8 / 44.1±0.3
45-50 / 46.5±0.8 / 47.5±0.5 / 48.8±1.2
>50 / 53.24±1.16 / 54.7±1.3 / 50.9±0.8 / ns / <0.0001
Total fat (Kg) / <45 / 51.9±5.0 / 58.3±3.4 / 63.1±3.3
45-50 / 70.9±2.8 / 73.4±2.5 / 68.2±9.6
>50 / 92.5±4.4 / 100.5±4.2 / 85.6±0.7 / ns / <0.0001
SAT (Kg) / <45 / 46.4±0.0 / 38.5±4.6 / 43.2±3.0
45-50 / 47.4±5.2 / 54.3±3.8 / 51.8±6.9
>50 / 70.1±5.1 / 74.0±4.4 / 63.7±2.8 / ns / 0.0001
VAT (Kg) / <45 / 10.5±0.0 / 19.7±8.0 / 19.9±5.9
45-50 / 23.4±8.0 / 19.0±2.2 / 16.4±2.8
>50 / 22.4±2.3 / 26.5±4.1 / 21.9±2.2 / ns / ns
waist (cm) / <45 / 113.0±1.0 / 127.5±3.5 / 129.8±7.7
45-50 / 138.009.0 / 131.6±4.3 / 138.5±1.0
>50 / 140.1±2.9 / 145.6±6.5 / 150.0±10.5 / ns / 0.0034
Satiety
Leptin (ng/mL) / <45 / 11.2±2.9 / 20.4±7.6 / 31.6±9.5
45-50 / 18.6±0.0 / 35.4±11.0 / 37.4±8.0
>50 / 31.4±7.2 / 60.6±7.3 / 62.0±6.4 / ns / ns
Ghrelin (pg/mL) / <45 / 61.7±38.9 / 45.2±6.4 / 106.8±31.9
45-50 / 60.5±0.0 / 49.3±11.4 / 57.5±21.6
>50 / 93.0±16.0 / 49.3±8.2 / 83.5±30.5 / ns / ns
Adiponectin (µg/mL) / <45 / 10.1±4.5 / 5.3±1.7 / 13.6±7.5
45-50 / 7.5±0.0 / 15.7±3.1 / 11.9±1.0
>50 / 9.3±1.2 / 11.2±1.2 / 8.6±1.4, / ns / ns

TABLE S3. Lipid, insulin resistant and inflammation parameters of morbidly obese patients with different BMIs Data are expressed as the mean ± SEM. The DM-DL- group includes patients without Type 2 diabetes mellitus (DM) and without dyslipidemia (DL)(healthy group). The DM-DL+ group includes patients who do not have DM but do have DL. The DM+DL+ group includes patients who have both DMand DL. The statistics were computed using two-way ANOVA (anova-2) and Bonferroni post-tests and were used to study the interaction between the effects of comorbidities and the BMI effect. Abbreviations: TG, triglycerides; PL, phospholipids; NEFA, non-esterified fatty acid; TC, total cholesterol; cHDL, HDL cholesterol; cLDL, LDL cholesterol; apoA1, apolipoprotein A1; apoB. apolipoprotein B; Symbol (&) indicates the differences between obese healthy group (DM-DL-) and the other groups; () indicates the difference between the DM-DL+ group and the DM+DL+ obese group. The level of significance was adjusted for multiple comparisons (Bonferroni correction/adjustment procedure) and were considered significant at p<0.01. One symbol, p<0.01; two symbols.p<0.001; ns, non-significant.

Parameters / DM-DL- (n=10) / DM-DL+ (n=15) / DM+DL+ (n=7) / Anova-2, p value
Lipid metabolism / BMI / OB / OB / OB / Comorbidities effect / BMI
TG (mg/dL plasma) / <45 / 71.7±0.0 / 71.7±0.0 / 155.5±24.2
45-50 / 101.8±10.6 / 212.7±46.4 / 199.1±0.0
>50 / 110.4±10.6 / 177.9±57.5 / 191.6±16.4 / ns / ns
PL (mM) / <45 / 2.3±0.2 / 2.3±0.4 / 2.6±0.0
45-50 / 2.4±0.0 / 2.6±0.0 / 2.3±0.4
>50 / 2.5±0.1 / 2.6±0.1 / 2.7±0.1 / ns / ns
NEFA (mM) / <45 / 0.7±0.3 / 0.5±0.1 / 0.7±0.1
45-50 / 0.3±0.0 / 0.7±0.1 / 0.6±0.3
>50 / 0.6±0.0 / 0.6±0.1 / 0.5±0.3 / ns / ns
TC (mg/dL) / <45 / 147.5±0.0 / 202.7±0.0 / 207.6±13.8
45-50 / 179.5±8.1 / 234.6±15.0 / 240.5±0.0
>50 / 177.5±5.2 / 282.8±42.3 / 230.3±11.0 / ns / ns
cLDL (mg/dL) / <45 / 95.8±0.0 / 147.5±0.0 / 130.4±13.6
45-50 / 112.4±3.5 / 145.3±6.3 / 153.7±0.0
>50 / 110.6±4.5 / 179.7±29.9 / 140.2±1.5+ / ns / 0.0025
cHDL (mg/dL) / <45 / 37.8±0.0 / 39.8±0.0 / 46.0±4.5
45-50 / 47.5±6.6 / 47.2±3.9 / 46.7±0.0
>50 / 44.9±2.3 / 68.3±0.4 / 52.3±9.5 / ns / ns
apo A1 (mg/dL plasma) / <45 / 160.2±11.6 / 163.9±13.4 / 187.6±5.6
45-50 / 171.7±0.0 / 199.8±15.8 / 211.6±11.6
>50 / 169.3±5.2 / 201.5±10.1 / 201.7±29.0 / ns / ns
apoB (mg/dL plasma) / <45 / 70.2±6.0 / 96.2±5.8 / 90.5±6.9
45-50 / 70.2±0.0 / 85.0±6.0 / 91.1±25.7
>50 / 69.4±1.2 / 99.3±7.2 / 96.5±5.3 / 0.0045 / ns

TABLE S4.Insulin resistant, inflammation and HTA parameters of morbidly obese patients with different BMIs. Data are expressed as the mean ± SEM. The DM-DL- group includes patients without Type 2 diabetes mellitus (DM) and without dyslipidemia (DL)(healthy group). The DM-DL+ group includes patients who do not have DM but do have DL. The DM+DL+ group includes patients who have both DMand DL. The statistics were computed using two-way ANOVA (anova-2) and Bonferroni post-tests and were used to study the interaction between the effects of comorbidities and the BMI effect. Abbreviations: HOMA-IR, homeostasis model assessment-insulin resistance; a.u., arbitrary units; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1; SBP, systolic blood pressure; DBP, diastolic blood pressure. Symbol (&) indicates the differences between obese healthy group (DM-DL-) and the other groups; () indicates the difference between the DM-DL+ group and the DM+DL+ obese group. The level of significance was adjusted for multiple comparisons (Bonferroni correction/adjustment procedure) and were considered significant at p<0.01. One symbol, p<0.01; two symbols, 0.001; ns, non-significant.

Parameters / DM-DL- (n=10) / DM-DL+ (n=15) / DM+DL+ (n=7) / Anova-2, p value
Insulin resistance / BMI / OB / OB / OB / Comorbidities effect / BMI
Insulin (UI/L) / <45 / 34.6±28.4 / 33.3±29.4 / 21.8±6.1
45-50 / 26.2±1.2 / 21.6±4.7 / 22.6±10.0
>50 / 26.1±5.5 / 20.3±8.0 / 26.7±10.7 / ns / ns
Glucose (mg/dL) / <45 / 104.5±0.5 / 96.5±7.5 / 175.7±33.0&,+
45-50 / 112.0±9.0 / 102.5±7.5 / 193.0±63.0&,+
>50 / 95.0±2.5 / 112.0±3.5 / 118.0±3.0 / 0.0003 / ns
HOMA-IR (a.u.) / <45 / 9.0±7.4 / 8.5±7.6 / 10.4±4.9
45-50 / 7.3±0.9 / 5.37±1.41 / 12.33±8.29
>50 / 6.2±1.4 / 4.5±1.4 / 7.7±2.9 / ns / ns
Inflammation
CRP (mg/L pl.) / <45 / 13.9±6.9 / 27.9±11.5 / 14.1±4.3
45-50 / 11.1±0.0 / 20.9±5.6 / 31.9±6.6
>50 / 20.5±3.1 / 22.1±3.1 / 23.9±5.9 / ns / ns
PAI-1 (ng/mL pl.) / <45 / 105.4±54.3 / 139.5±83.8 / 230.8±47.7
45-50 / 67.9±0.0 / 134.8±55.7 / 146.0±0.0
>50 / 195.2±29.8 / 183.9±18.3 / 60.6±11.9 / ns / ns
HTA
SBP / <45 / 130.0±10.0 / 137.5±27.5 / 143.3±14.5
45-50 / 137.5±7.5 / 137.0±4.6 / 125.0±5.0
>50 / 145.0±8.5 / 154.0±10.4 / 135.0±5.0 / ns / ns
DBP / <45 / 82.50±7.50 / 85.00±0.00 / 96.67±8.82
45-50 / 87.50±2.50 / 86.00±2.92 / 87.50±7.50
>50 / 91.43±2.61 / 100.00±9.22 / 92.50±2.50 / ns / ns

1